Tonix CEO Buys 15,000 Shares Below Market, Hinting at Bullish Outlook Ahead of Key Data Release
Tonix insiders buying 15,000 shares at $14.89 signals CEO optimism ahead of ACR data, potentially boosting the stock as investors watch for future upside.
- Tonix Pharmaceuticals Holding Corp
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read

